Education
About Us
Working with TipRanks
Follow Us
Brainstorm Cell Therapeutics (BCLI)
NASDAQ:BCLI
RESEARCH TOOLSreports
BCLI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.72 - $8.09
Previous CloseN/A
Volume34.73K
Average Volume (3M)2.30M
Market Cap
$8.89M
Enterprise ValueN/A
Total Cash (Recent Filing)$168.00K
Total Debt (Recent Filing)$841.00K
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Aug 18, 2025EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding7,938,876
10 Day Avg. Volume6,603,885
30 Day Avg. Volume2,301,712
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-1.04
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$6.00Price Target Upside435.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Brainstorm Cell Therapeutics News
See All BCLI News
Bulls Say, Bears Say
Bulls Say
Manufacturing CapabilitiesThe strategic collaboration with Minaris Advanced Therapies enhances US-based manufacturing capabilities and brings the scalability needed for NurOwn's complex autologous cell therapy.
Regulatory SupportFDA clearance for the upcoming P3b (ENDURANCE) study in amyotrophic lateral sclerosis (ALS) announced, positioning BrainStorm to acquire funds for the trial, including non-dilutive sources like a $15M grant under review.
Therapeutic AdvancementsNurOwn is the most advanced therapy in the ALS space, is safe, and has a history of positive therapeutic impact, making the trial crucial for patients and caregivers.
Bears Say
Financial PerformanceBrainStorm reported a net loss of ($2.9M) and ended the period with $1.8M in cash on the balance sheet.
Macroeconomic FactorsPre-revenue Biotech is particularly susceptible to macroeconomic factors due to its reliance on capital and inherent uncertainty.
Market ConditionsDifficult market conditions, particularly for small/micro-cap stocks, and economic uncertainty continue to pressure broader markets.
Options Prices
Currently, No data available
---
Ownership Overview
10.93% Insiders
1.77% Mutual Funds
14.45% Other Institutional Investors
72.48% Public Companies and Individual Investors
BCLI FAQ
What was Brainstorm Cell Therapeutics’s price range in the past 12 months?
Brainstorm Cell Therapeutics lowest stock price was $0.72 and its highest was $8.09 in the past 12 months.
What is Brainstorm Cell Therapeutics’s market cap?
Brainstorm Cell Therapeutics’s market cap is $8.89M.
When is Brainstorm Cell Therapeutics’s upcoming earnings report date?
Brainstorm Cell Therapeutics’s upcoming earnings report date is Aug 18, 2025 which is in 77 days.
How were Brainstorm Cell Therapeutics’s earnings last quarter?
Brainstorm Cell Therapeutics released its earnings results on May 16, 2025. The company reported -$0.45 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.45.
Is Brainstorm Cell Therapeutics overvalued?
According to Wall Street analysts Brainstorm Cell Therapeutics’s price is currently Undervalued.
Does Brainstorm Cell Therapeutics pay dividends?
Brainstorm Cell Therapeutics does not currently pay dividends.
What is Brainstorm Cell Therapeutics’s EPS estimate?
Brainstorm Cell Therapeutics’s EPS estimate is -0.37.
How many shares outstanding does Brainstorm Cell Therapeutics have?
Brainstorm Cell Therapeutics has 7,938,876 shares outstanding.
What happened to Brainstorm Cell Therapeutics’s price movement after its last earnings report?
Brainstorm Cell Therapeutics reported an EPS of -$0.45 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 13.793%.
Which hedge fund is a major shareholder of Brainstorm Cell Therapeutics?
Currently, no hedge funds are holding shares in BCLI
Company Description
Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
BCLI Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in regulatory clearance and clinical trial preparations for NurOwn, alongside promising biomarker research and development in the exosome program. However, financial constraints and the need for funding to initiate the trial were notable challenges.Read More>BCLI Stock 12 Month Forecast
Average Price Target
$6.00
▲(435.71%Upside)